Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target
Abstract Background Chondrosarcoma is a malignant cartilaginous neoplasm of the bone which resistant to radiation therapy and chemotherapy. Cyclin-dependent kinase 4 (CKD4) is highly expressed in human cancer, and palbociclib, the inhibitor of CDK4 has been used clinically under FDA approval for app...
Main Authors: | Zhengxiao Ouyang, Sisi Wang, Ming Zeng, Zhihong Li, Qing Zhang, Wanchun Wang, Tang Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-02-01
|
Series: | Cell Communication and Signaling |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12964-019-0327-5 |
Similar Items
-
Safety and efficacy profile of cyclin‐dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta‐analysis of clinical trials
by: Linghong Guo, et al.
Published: (2019-04-01) -
Palbociclib in the treatment of recurrent ovarian cancer
by: Dai Wee Lee, et al.
Published: (2020-11-01) -
Palbociclib overcomes afatinib resistance in non-small cell lung cancer
by: Huijuan Nie, et al.
Published: (2019-01-01) -
Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells
by: Lindsey R. Conroy, et al.
Published: (2020-07-01) -
CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
by: Yi-Bo Hou, et al.
Published: (2019-08-01)